These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36819813)

  • 1. Li-Fraumeni-associated pancreatic neuroendocrine tumour and
    Riechelmann RP; Soares DC; Dias C; Carraro DM; Torrezan GT
    Ecancermedicalscience; 2022; 16():1487. PubMed ID: 36819813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report.
    Aversa JG; De Abreu FB; Yano S; Xi L; Hadley DW; Manoli I; Raffeld M; Sadowski SM; Nilubol N
    BMC Cancer; 2020 Mar; 20(1):256. PubMed ID: 32228502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
    Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
    J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XAF1 as a modifier of p53 function and cancer susceptibility.
    Pinto EM; Figueiredo BC; Chen W; Galvao HCR; Formiga MN; Fragoso MCBV; Ashton-Prolla P; Ribeiro EMSF; Felix G; Costa TEB; Savage SA; Yeager M; Palmero EI; Volc S; Salvador H; Fuster-Soler JL; Lavarino C; Chantada G; Vaur D; Odone-Filho V; Brugières L; Else T; Stoffel EM; Maxwell KN; Achatz MI; Kowalski L; de Andrade KC; Pappo A; Letouze E; Latronico AC; Mendonca BB; Almeida MQ; Brondani VB; Bittar CM; Soares EWS; Mathias C; Ramos CRN; Machado M; Zhou W; Jones K; Vogt A; Klincha PP; Santiago KM; Komechen H; Paraizo MM; Parise IZS; Hamilton KV; Wang J; Rampersaud E; Clay MR; Murphy AJ; Lalli E; Nichols KE; Ribeiro RC; Rodriguez-Galindo C; Korbonits M; Zhang J; Thomas MG; Connelly JP; Pruett-Miller S; Diekmann Y; Neale G; Wu G; Zambetti GP
    Sci Adv; 2020 Jun; 6(26):eaba3231. PubMed ID: 32637605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Identification of a Novel Pathogenic Germline
    Paduano F; Fabiani F; Colao E; Trapasso F; Perrotti N; Barbieri V; Baudi F; Iuliano R
    Front Genet; 2021; 12():734809. PubMed ID: 34539758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
    Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome : Lung cancer and Li Fraumeni.
    Sorscher S
    Fam Cancer; 2024 Nov; 23(4):469-471. PubMed ID: 39235550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by
    Sandoval RL; Polidorio N; Leite ACR; Cartaxo M; Pisani JP; Quirino CV; Cezana L; Pereira NG; Pereira AAL; Rossi BM; Achatz MI
    Front Oncol; 2022; 12():836937. PubMed ID: 35371985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
    Ruijs MW; Schmidt MK; Nevanlinna H; Tommiska J; Aittomäki K; Pruntel R; Verhoef S; Van't Veer LJ
    Eur J Hum Genet; 2007 Jan; 15(1):110-4. PubMed ID: 17003841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.
    Macedo GS; Araujo Vieira I; Brandalize AP; Giacomazzi J; Inez Palmero E; Volc S; Rodrigues Paixão-Côrtes V; Caleffi M; Silva Alves M; Achatz MI; Hainaut P; Ashton-Prolla P
    Cancer Genet; 2016 Mar; 209(3):97-106. PubMed ID: 26823150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.